Skip to content
CNS Clinical Research

Little Rock, Arkansas

CNS clinical trials in Little Rock, AR

52 CNS studies are recruiting participants at sites in Little Rock as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Little Rock at a glance

  • 52 studies are recruiting at a site in Little Rock.
  • By phase: Phase 1 (1), Phase 1/2 (1), Phase 2 (14), Phase 3 (32), Phase 4 (4).
  • By sponsor: industry (51), university, hospital or other (1).
  • By research area: Schizophrenia (16), Depression (11), Migraine (6), Bipolar Disorder (5), Epilepsy (5), Parkinson's Disease (5), ADHD (4).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Little Rock

Basic details from each study's public record (the 30 most recently updated of 52). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Preferred Research Partners, Inc.
    Registry record
    NCT07592689 · updated
  2. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    University of Arkansas for Medical Sciences
    Registry record
    NCT06748222 · updated
  3. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Pillar Clinical Research, LLC
    Registry record
    NCT06372964 · updated
  4. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  5. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07610473 · updated
  6. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated
  7. A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07300969 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Little Rock, AR on ClinicalTrials.gov.

Schizophrenia studies recruiting in Little Rock

  1. A Study to Evaluate the Effect of KarXT on Urological Safety

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research- Little Rock
    Registry record
    NCT07221877 · updated
  2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Pillar Clinical Research, LLC
    Registry record
    NCT06229210 · updated
  3. Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 60
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT07680946 · updated
  4. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Pillar Clinical Research- Little Rock
    Registry record
    NCT07686263 · updated
  5. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Little Rock, AR on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Little Rock

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research- Little Rock
    Registry record
    NCT06951711 · updated
  2. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Pillar Clinical Research- Little Rock
    Registry record
    NCT07140913 · updated
  3. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study sites
    Pillar Clinical Research- Little Rock · Woodland International Research Group
    Registry record
    NCT06929273 · updated
  4. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Woodland International Research Group
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Little Rock, AR on ClinicalTrials.gov.

ADHD studies recruiting in Little Rock

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigational Site
    Registry record
    NCT07755410 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Little Rock, AR on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Little Rock

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  2. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study site
    University of Arkansas for Medical Sciences
    Registry record
    NCT06944522 · updated
  3. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    University of Arkansas
    Registry record
    NCT06680830 · updated
  4. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    University of Arkansas for Medical Sciences (Site #208)
    Registry record
    NCT07432958 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Little Rock, AR on ClinicalTrials.gov.

Epilepsy studies recruiting in Little Rock

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of Arkansas for Medical Sciences
    Registry record
    NCT05667142 · updated
  2. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study site
    University of Arkansas for Medical Sciences
    Registry record
    NCT05135091 · updated
  3. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    Arkansas Children's Hospital
    Registry record
    NCT04462770 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Little Rock, AR on ClinicalTrials.gov.

Migraine studies recruiting in Little Rock

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Preferred Research Partners, Inc.
    Registry record
    NCT07816367 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Arkansas Clinical Research
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Arkansas Clinical Research
    Registry record
    NCT07674654 · updated
  4. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Preferred Research Partners /ID# 270389
    Registry record
    NCT06810505 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Little Rock, AR on ClinicalTrials.gov.

Ask about studies near Little Rock

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call